Abstract
Introduction
Aortic valve replacement (AVR) is the accepted 'Gold Standard' for the treatment of severe or symptomatic aortic valve stenosis. Due to increasing age of the patient population (reflecting the demographic changes) in the western world, the use of biological valves has increased over the past years. At the same time, a large proportion of these patients require concomitant surgical procedures in addition to AVR [1] .
Although trans-apical or trans-femoral aortic valve implantations (TAVI) have been introduced for high risk patients, they are limited to patients with isolated aortic valve pathology [2] .
Three consecutive European, multicenter, prospective, non-randomized clinical trials (Pilot, Pivotal, and CAVALIER) were designed to evaluate the sutureless Perceval aortic valve prosthesis in elderly patients. The Perceval valve (Sorin Group, Saluggia, Italy) is a bioprosthetic heart valve made of bovine pericardium allowing for a fast implantation through a sutureless technique. We describe the combined results of these three consecutive trials. 5 
Material and Methods

Study design
This series comprises the cumulative results of patients undergoing aortic valve replacement with or without concomitant procedures from three consecutive 25 centers in 8 European countries took part in these three studies. Approval for these studies was granted by the Ethical Committees of the Hospitals involved and each patient gave signed informed consent before being enrolled in the trials.
Perceval Pilot trial
The objective of the Pilot trial was to assess the safety of aortic valve replacement with the sutureless Perceval valve in 30 symptomatic patients, aged 75 and older. The primary endpoint was the assessment of the safety of the Perceval prosthesis in terms of mortality and morbidity at 30 days, correlated to prosthetic valve performance. Secondary endpoints were the evaluation of mortality and morbidity, the evaluation of the clinical status on the basis of the New York Heart Association (NYHA) functional classification, and the evaluation of the haemodynamic performance at 1, 3, 6 and 12 months from implantation, respectively. 6 
Perceval Pivotal trial
The primary objective of the Pivotal study was to assess the performance of the Perceval valve at 3 to 6 months after implantation in 150 high surgical risk patients aged ≥75 years, requiring surgical intervention to replace the aortic valve. The primary endpoint was the assessment of the Perceval prosthesis safety and performance at 3 to 6 months after surgery. Secondary endpoints included the evaluation of the Perceval valve in terms of improvement of clinical status, haemodynamic performance by echocardiography, and assessment of mortality and morbidity rates at discharge and 12 months after implant, respectively.
These two Perceval trials aimed at obtaining initial CE mark approval, even though only two prosthesis sizes (Size S and Size M) were available. The outcomes showed adequate safety and performance, and allowed the Perceval to obtain CE mark in January 2011 (for sizes S and M) under limited indications.
CAVALIER trial
The CAVALIER trial was designed to assess the safety and effectiveness of the Perceval valve at 12 months after implantation when used to replace a diseased or dysfunctional aortic valve or aortic valve prosthesis in patients older than 65 years. The primary endpoint was the evaluation of the safety (assessed in terms of mortality and morbidity) and effectiveness (assessed in terms of improvement of clinical status as well as haemodynamic performance) of the 7 Perceval valve at 12 months after the implants. The secondary endpoints of the clinical investigation were the assessment of safety and effectiveness at discharge and 3 to 6 months after surgery and yearly thereafter. Besides lowering the age limit to younger patients (65 years or older), this study included two additional prosthesis sizes: Size L (from February 2010) and Size XL (from July 2012).
Perceval sutureless valve
The Perceval valve is a surgical bioprosthetic heart valve comprising a biological component of bovine pericardium and an elastic Ni-Ti alloy stent made of two rings and 9 vertical struts covered by a thin coating of Carbofilm™ that improves biocompatibility (Fig. 1) . The stent has the dual task of supporting the valve and holding it in place without any permanent suture. Thanks to its elastic properties, the stent adapts to the anatomy of the aorta and follows its movements, relieving the stress on the leaflets. The valve is collapsed with an atraumatic device compression, assuring that the valve leaflets are not affected.
Surgical procedure
The patients were operated either through a standard median sternotomy or upper mini-sternotomy. Anaesthetic and surgical techniques were standardized according to the preferences of each centre. A transverse aortotomy was performed about 0.5 cm distal to the sinu-tubular junction in order to leave a free edge for closure of the aortotomy after implantation of the device. 8 The native calcified aortic valve was excised and the aortic annulus decalcified.
A regular annular profile was beneficial to ensure optimal sealing and preventing the risk of paraprosthetic leak. The sizing of the annulus was done with the dedicated sizers.
For this series, the study valve was available in three sizes: Size S, to be implanted in annulus sizes from 19 to 21 mm, Size M to be implanted in annulus sizes from 21 to 23 mm, and Size L for patients with an annulus size from 23 to 25 mm.
The implantation technique included several steps as already described elsewhere [3, 4, 5] .
Concomitant coronary artery bypass graft (CABG) procedures were additionally performed in patients with coronary artery disease. This was usually done during the time when the study valve was being collapsed to keep the aortic cross clamp time as short as possible.
After closure of the aortotomy in the usual fashion, release of the aortic cross clamp and thorough de-airing, the valve functioning was investigated by transesophageal echocardiography in all patients.
Following the procedure, the patients received anticoagulation treatment according to the standard protocol in use at each center for bioprostheses.
Patients:
From April 2007 to August 2012, a total of 765 patients were enrolled in these three Perceval studies (30 Pilot, 150 Pivotal and 585 Cavalier subjects). Out of 9 765 patients included in the study, the Perceval valve was implanted in 731 patients (95.6%), while in 34 cases (4.4%), conversion to commercially available valves was required.
The enrolment was carried out in a sequential, prospective manner such that all patients identified as candidates for standard aortic valve replacement with a bioprostheses (according to the practice of each centre) were offered the option of participating in the assessment if the they fulfilled the selection criteria defined in each protocol (Annex B).
Follow-up
According to the study protocol, clinical evaluation, ECG, blood exam and transthoracic echocardiographic examination were performed at discharge (or 30 days), at 3-6 months, at 12 months and then annually up to 5 years.
An Echo core laboratory performed a full analysis of the images and relevant calculations and an independent Clinical Events Committee reviewed and adjudicated the complications.
Adverse events were reported according to current guidelines [6] . Kaplan-Meier survival curve is shown in figure 2 .
Statistical analysis
Statistical analyses were performed on all patients successfully implanted with a 10 Perceval valve. Categorical variables are reported as absolute and relative frequencies. For continuous data, means and standard deviations were calculated. Cumulative survival and freedom from events were estimated using the Kaplan-Meier method, with 95% confidence intervals (95% CI). Statistical analyses were performed using SAS software (Release 9.2, by SAS Institute Inc., Cary, NC, USA). A p-value <0.05 was considered to be statistically significant.
Results
Patient demographics and procedural outcomes
The mean age of the 731 patients was 78.5±5.3 years (range, 62-92 years).
43.1% of patients were ≥ 80 years old. The preoperative data are reported in 11 Table 2 .
Mean aortic cross-clamp times and Cardio-pulmonary bypass (CPB) times were 30.8 min and 50.8 min respectively for isolated aortic valve replacement via median sternotomy and 37.6 min. and 64.4 min. for a minimally invasive approach (Table 3) .
Complications
All-cause and cardiac early mortality were 3.4% (25/731) and 1.9% (14/731), respectively. Among the early cardiac deaths, 3 occurred in OR. One occurred during operation in a patient with very critical preoperative status; the patient underwent successful implant of the device that was then removed due to the presence of a previous endocarditic lesion and the patient did not survive the surgery due to myocardial failure. In second case, death was caused by an acute myocardial dysfunction, a third case was due to annulus rupture during traditional valve implantation following aortic regurgitation with the Perceval valve. All-cause and cardiac late mortality were 7% (51/731) and 1.4% (10/731), respectively. 12 Specific cause of early and late death is reported in Table 4 .
During the follow-up phase, 21 patients required explantation of the Perceval valve, 10 early (1.4%), and 11 late.
Early explants
One case was related to a perioperative bleeding from the aorta: the patient was immediately returned to the operating room and had the Perceval valve as well as aortic root replaced with a biological valved conduit. The bleeding was caused by an aortic tear below the right coronary ostium, due to extensive decalcification of the annulus.
Two cases of early explants occurred at 2 and 4 days post-surgery and were likely due to mis-sizing leading to para or intra-prosthetic regurgitation; 3 cases occurred at 2, 3, and 7 days after surgery and were related to malpositioning and subsequent regurgitation; one Perceval was explanted at 12 days where a paravalvular leak (PVL) was caused by early endocarditis. One explant occurred at 13 days after surgery and was related to intra-valvular regurgitation in a patient with severe calcified aortic annulus requiring ascending aorta replacement. One explant occurred at 20 days after implant and was likely related to inappropriate sizing and positioning. A last case occurred at 30 days, secondary to deep valve positioning and consequent PVL.
Late Explants:
Among the 11 late explants (1.5%), 8 were due to endocarditis. An explant occurred at 122 days after surgery and was related to a shunt between aorta and right ventricle. This was initially diagnosed at discharge and considered not 13 haemodynamically significant, even though it later increased causing recurrent cardiac decompensation, pulmonary hypertension, and severe tricuspid regurgitation. One explant occurred around 19 months after surgery because of fibrous pannus overgrowth. One last late explant occurred at almost 2 years after implant and was due to a pseudo-aneurysm of the non-coronary sinus resulting in paravalvular regurgitation; the valve was replaced along with the ascending aorta. Table 5 reports the early and late complications. Major paravalvular leak occurred in the 1.4% (early) and 1% (late follow up), respectively. The incidence of early major stroke was 1.6%, while 6 cases of late stoke events (0.8%) were reported. Forty-four patients (6.0%) with no prior history of cardiac rhythm disorders experienced early AV block III. Neither valve thrombosis nor structural valve deterioration was detected. No cases of valve migration or dislodgement after surgery were reported.
Clinical results:
The functional status significantly improved along with in the haemodynamic performance in the majority of the population. A marked decrease in NYHA stage was observed with the majority of patients falling in class I-II during follow-up. The mean gradient was 10.3 mmHg at discharge/1 month, 8.9 mmHg at 3-6 months and 12 months, 8.8 mmHg at 2 years, and 7.7 mmHg and 7.8 mmHg at 3 and 4 years, respectively. At 5 year follow up, the few data available at the time of the data analysis (6 echo exams) showed a mean gradient of 7.8 mmHg. This gradient reduction was correlated to an increase in the effective 14 orifice area from 0.75 cm 2 preoperatively to 1.49 cm 2 at discharge/1 month, 1.51 cm 2 at 3-6 months, 1.55 cm 2 at 12 months, up to 1.80 cm 2 at 5 years, and to a LV-mass regression, which went from 254.5 g to 177.4 g at 3 years.
Hemodynamic results by valve size are reported in Table 6 .
Discussion
Aortic valve replacement has been widely accepted as the gold standard for the treatment of patients with aortic valve stenosis [7] . The mean age of the patients referred for AVR has been increasing along with the demographic changes. In the present study cohort more than 40% of the patients were 80 years or older.
The 5-year outcomes from patients undergoing AVR with Perceval valve demonstrate that the device is safe and well performing, even in a old population with co morbidities.
Previous studies demonstrated that the duration of aortic cross-clamping and CPB are independent predictors of survival after either aortic valve replacement or combined valve operations with CABG [8, 9] . Therefore, a new technology for shortening aortic cross-clamp time and consequently CPB time is mandatory to further reduce mortality after AVR surgery.
The Perceval valve features a fairly high adaptability to different surgical approaches as showed by this study. The implantations were performed either via full sternotomy or minimally invasive approach (mini-sternotomy or right anterior mini-thoracotomy) [10, 11] .
Previous experiences showed that the use of less invasive AVR was associated 15 with excellent outcomes in terms of postoperative complications and hospital stay [12, 13] . Previous experience already demonstrated the safety and efficacy of the Perceval valve even in cases of concomitant cardiac procedures. [14] .
In patients requiring aortic valve replacement along with concomitant procedures, shortening the aortic cross clamp and CPB time may help reduce the mortality and morbidity. Ranucci et al. [9] reported that the aortic cross clamp time is an independent predictor of severe cardiovascular morbidity, with an increased risk of 1.4% per one minute increase. Therefore, the use of sutureless valves may help reduce the procedural times thanks to the absence of need for sutures. 16 The clinical results up to 5 years follow-up reported in this large cohort of patients, confirm the safety and efficacy of the Perceval sutureless aortic valve.
Rates of early and late mortality and complications such as stroke, PVL are comparable with reported rates for traditional AVR [15, 16] . Even in cases requiring explantation of the Perceval, the procedure was easy and the Perceval valve was removed without technical issues, as previously described [17] .
New occurrences of early AV block III leading to pacemaker implant in patients with no prior history of cardiac rhythm disorders was 6.0%, which is within the ranges reported in literature for traditional AVR [18] . This rate could also be related to the initial learning curve effect. Additionally, the large number of centers in this cohort and variability of operators and protocols of rhythm disorders management could be considered as an additional potential contributing factor, considering that in one of the biggest cohort in experienced centers, the rate was lower (4.2%) [19] .
No valve dislodgement or migration, thrombosis or structural valve deterioration was observed even after a follow-up of up to 5 years.
The valve implantation resulted in significant improvement of patient's symptoms. Even though a majority of patients were quite short in stature with small aortic annulus and received small size prostheses, the post-operative trans-valvular gradients were low and remained stable over time up to 5 years follow-up. In patients with a critically small annulus, this valve allows maximization of the bioprosthetic diameter, as previously reported [20] . The haemodynamic data show an improvement of the left ventricular function.
Conclusions
In summary, this study reports the widest and longest experience with a sutureless valve and highlights its safety and efficacy also in an elderly 
Limitation
One limitation of this study is that there is no control group with patients receiving conventional valves to determine the Perceval additional benefits respect to the gold standard. Furthermore, EuroScore was used for the three studies even though EuroScore may overestimate risk of mortality.
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